Gland Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma has submitted a routine compliance filing to the stock exchanges, attaching a confirmation certificate from its Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited (formerly Link Intime). The certificate, dated July 5, 2025, covers the quarter ending June 30, 2025, and confirms that all securities received from depository participants for dematerialisation during the quarter were properly processed and reflected in the register of members. The RTA also noted that no dematerialisation or rematerialisation requests were received during the quarter. The filing is signed by Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer.
This is a standard regulatory compliance filing with no material impact on the company's financials, operations, or stock price. It is purely procedural, confirming that the RTA has handled share dematerialisation activities (or lack thereof) as required by SEBI rules during the April–June 2025 quarter.